Get the Stockscreener App
273.63
0.45%
-1.2793
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Cencora Inc stock is traded at $273.63, with a volume of 372.13K.
It is down -0.45% in the last 24 hours and down -11.20% over the past month.
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
See More
Previous Close:
$274.91
Open:
$273.09
24h Volume:
372.13K
Relative Volume:
0.23
Market Cap:
$53.24B
Revenue:
$328.68B
Net Income/Loss:
$2.55B
P/E Ratio:
20.99
EPS:
13.0349
Net Cash Flow:
$1.56B
1W Performance:
+2.81%
1M Performance:
-11.20%
6M Performance:
-25.74%
1Y Performance:
-6.39%
1-Day Range:
$270.23
$274.92
1-Week Range:
$261.90
$277.39
52-Week Range:
$244.82
$377.54
Cencora Inc Stock (COR) Company Profile
Name
Cencora Inc
Sector
Industry
Phone
610-727-7000
Address
1 WEST FIRST AVENUE, CONSHOHOCKEN
Compare COR vs MCK, CAH, HSIC, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
273.62 | 53.49B | 328.68B | 2.55B | 1.56B | 13.03 |
MCK
Mckesson Corp
|
757.25 | 92.09B | 403.43B | 5.10B | 5.41B | 38.47 |
CAH
Cardinal Health Inc
|
201.27 | 47.00B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
74.19 | 8.45B | 13.18B | 419.00M | 521.00M | 3.2704 |
AHG
Akso Health Group Adr
|
1.50 | 1.31B | 14.85M | -136.07M | 7.25M | -0.4726 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-22-26 | Upgrade | Jefferies | Hold → Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Jun-03-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-04-24 | Resumed | Mizuho | Outperform |
| Sep-18-24 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-31-23 | Initiated | Citigroup | Buy |
| Jan-31-23 | Resumed | Evercore ISI | Outperform |
| Oct-11-22 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-11-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-07-22 | Upgrade | Deutsche Bank | Hold → Buy |
| May-26-22 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-12-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Resumed | Evercore ISI | In-line |
| Feb-04-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-02-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-06-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-10-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Dec-03-20 | Initiated | Mizuho | Neutral |
| Aug-06-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-15-20 | Initiated | Barclays | Underweight |
| Jun-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-23-20 | Resumed | Credit Suisse | Outperform |
| Apr-16-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-13-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-01-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-20 | Downgrade | BofA/Merrill | Buy → Underperform |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Jul-10-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Apr-11-19 | Initiated | Guggenheim | Buy |
| Apr-10-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Apr-10-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-17-19 | Initiated | UBS | Buy |
| Dec-10-18 | Downgrade | Jefferies | Buy → Hold |
| Oct-26-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-20-18 | Initiated | Berenberg | Buy |
| Jul-17-18 | Resumed | Stifel | Hold |
| Apr-09-18 | Initiated | MoffettNathanson | Buy |
| Mar-12-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Mar-12-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-25-17 | Initiated | JP Morgan | Neutral |
| Sep-22-17 | Initiated | William Blair | Outperform |
View All
Cencora Inc Stock (COR) Latest News
Cencora, Inc. (COR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Cencora hits 52-week low after guidance cut - MSN
Cencora, Inc. (COR) Stock Analysis: Healthcare Giant With A 29.80% Upside Potential - DirectorsTalk Interviews
Cencora Inc. stock (US15135B1017): new leadership move as former CEO returns as chair amid healthcar - AD HOC NEWS
Cencora Inc (COR) Stock Up 3.6% and Still Undervalued -- GF Scor - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cencora, Inc. (COR) And Encourages Investors to Connect - ACCESS Newswire
Cencora Inc. stock outperforms competitors on strong trading day - MarketWatch
Cencora raises earnings outlook on share repurchases - Seeking Alpha
Cencora Inc. stock (US15135B1017): guidance tweak and extra $2 billion buyback attract fresh attenti - AD HOC NEWS
Cencora: Board of Directors Authorized New Shr Repurchase Program to Purchase Up to Additional $2.0B of Stk >COR - Moomoo
Cencora Raises Fiscal 2026 EPS Outlook, Authorizes $2 Billion Share Buyback - Moomoo
Cencora revises forecast for 2026, approves $2 billion share buyback - marketscreener.com
$2 billion stock buyback: Cencora lifts 2026 earnings forecast - Stock Titan
Cencora Announces Updated Fiscal Year 2026 Financial Outlook - marketscreener.com
Cencora, Inc. announces an Equity Buyback for $2,000 million worth of its shares. - marketscreener.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc.COR - PR Newswire
Cencora stock (US15135B1017): transformation story after name change and solid earnings - AD HOC NEWS
COR's MWI Animal Health to merge with Covetrus in $3.5 billion deal - MSN
Cencora, Inc. authorizes a Buyback Plan. - marketscreener.com
Deals tracker: Medtronic to acquire SPR Therapeutics for $650M - Modern Healthcare
Cencora stock (US15135B1017): Earnings miss and legal probe weigh on shares - AD HOC NEWS
Cencora, Inc. (COR) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
Cencora stock (US15135B1017): Q2 miss, legal probe and what matters now for investors - AD HOC NEWS
Cencora stock (US15135B1017): dividend track record and legal investigation in focus - AD HOC NEWS
Investors can join fraud probe against Cencora after Q2 miss and revenue drop claims. - Pluang
COR Investors Have Opportunity to Join Cencora, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
COR Investors Have Opportunity to Join Cencora, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire Inc.
Cencora (COR) Emerges as a Healthcare Leader with Robust Fundamentals and Strategic Re-Rating - Insider Monkey
Cencora stock (US15135B1017): revenue miss, guidance tweak and share price pressure in focus - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cencora, Inc. (COR) And Encourages Stockholders to Connect - ACCESS Newswire
Cencora Inc. stock underperforms Wednesday when compared to competitors - MSN
Will Cencora’s (COR) Revenue Miss and Probes Change Its Margin-Expansion Narrative? - simplywall.st
The Top 5 Analyst Questions From Cencora’s Q1 Earnings Call - Yahoo Finance
Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run? - MSN
Is It Time To Revisit Cencora (COR) After The Recent Share Price Slump? - simplywall.st
Rosen Law Firm Encourages Cencora, Inc. Investors to Inquire About Securities Class Action Investigation – COR - Business Wire
Cencora Inc. stock outperforms competitors despite losses on the day - MarketWatch
Cencora stock (US15135B1017): pharma distributor reshapes portfolio after latest earnings - AD HOC NEWS
Wells Fargo Maintains Overweight Rating on Cencora (COR) - Insider Monkey
Cencora, Inc. Common Stock (NY: COR - FinancialContent
Cencora faces securities fraud probe after missing revenue targets and stock plunge. - Pluang
Cencora, Inc.: - marketscreener.com
Cencora Inc. stock (US15135B1017): dividend date and legal probe in focus for investors - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
CAH Stock Down Nearly 9.4% YTD: Should You Buy, Hold or Sell? - TradingView
ETFs Investing in Cencora, Inc. Stocks - TradingView
Are Wall Street Analysts Bullish on Cencora Stock? - Yahoo Finance
Cencora Inc Stock (COR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.30%
6.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):